Fusion protein · Protein replacement: Neonatal Fc receptor (FCGRT) · developed by Bioverativ Therapeutics
Efanesoctocog alfa is a recombinant factor VIII fusion protein carrying an Fc domain, the D'D3 domain of von Willebrand factor and two XTEN polypeptides. It temporarily replaces the missing coagulation factor VIII needed for clot formation, and its design extends circulating half-life. It is studied in hemophilia A (factor VIII deficiency).
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Oct 20, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06941870 | Phase 4 | Factor VIII Deficiency | Recruiting | SNY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Factor VIII Deficiency
Updated Nov 15, 2026.